New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 8, 2013
10:00 EDTHEK, RDC, LUV, LSTR, FTI, PH, TKC, MKSI, KKR, CELG, VTR, MGM, SPN, MFC, JOY, DOVOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Celgene (CELG) upgraded to Outperform from Sector Perform at RBC Capital... Celgene (CELG) upgraded to Overweight from Neutral at Piper Jaffray... Dover (DOV) upgraded to Overweight from Equal Weight at Morgan Stanley... FMC Technologies (FTI) upgraded to Buy from Neutral at Sterne Agee... Joy Global (JOY) upgraded to Overweight from Neutral at Piper Jaffray... KKR & Co. (KKR) upgraded to Buy from Neutral at Goldman... Landstar System (LSTR) upgraded to Outperform from Market Perform at Wells Fargo... MKS Instruments (MKSI) upgraded to Buy from Neutral at BofA/Merrill... Manulife Financial (MFC) upgraded to Buy from Neutral at BofA/Merrill... Southwest (LUV) upgraded to Buy from Hold at Deutsche Bank... Superior Energy (SPN) upgraded to Outperform from Sector Perform at RBC Capital... Turkcell (TKC) upgraded to Overweight from Neutral at HSBC... Rowan Companies (RDC) upgraded to Neutral from Underweight at JPMorgan... MGM Resorts (MGM) upgraded to Outperform from Neutral at Credit Suisse... Parker-Hannifin (PH)upgraded to Overweight from Neutral at JPMorgan... Ventas (VTR) upgraded to Buy from Hold at Jefferies... Heckmann (HEK) upgraded to Neutral from Sell at Ladenburg.
News For DOV;CELG;FTI;JOY;KKR;LSTR;MFC;MKSI;LUV;SPN;TKC;RDC;MGM;PH;HEK;VTR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
January 22, 2015
05:36 EDTKKRKKR acquires Trainline, details not disclosed
Subscribe for More Information
January 21, 2015
18:28 EDTRDCRowan Companies sees Q4 jack-up out of service time to be 7%
Subscribe for More Information
16:26 EDTJOYJoy Global upgraded to Outperform from Market Perform at BMO Capital
16:12 EDTDOVDover initiated with a Neutral at UBS
Target $70.
15:27 EDTLUVNotable companies reporting before tomorrow's open
Subscribe for More Information
08:36 EDTCELGCelgene price target raised to $139 from $115 at RW Baird
Baird raised its price target on Celgene to $139 from $115 following last week's guidance from the company. Baird reiterated its Outperform rating on Celgene shares.
January 20, 2015
16:00 EDTMGMOptions Update; January 20, 2015
iPath S&P 500 VIX Short-Term Futures down 36c to 35.12 Option volume leaders: AAPL TSLA TWTR GILD NFLX MGM ABX AMAT JNJ C according to Track Data.
15:36 EDTLUVSouthwest volatility elevated into Q4
Subscribe for More Information
11:52 EDTKKRKKR seeks $3B for distressed fund targeting oil companies, Asia, Bloomberg says
Subscribe for More Information
09:01 EDTLSTRLandstar System downgraded to Underperform from Peer Perform at Wolfe Research
06:39 EDTLUVU.S. airlines may buy back shares amid cheap oil, WSJ reports
Subscribe for More Information
January 18, 2015
16:07 EDTMGMMacau junket operator reduces operations, Bloomberg says
As China’s anti-graft drive reduces customer traffic in Macau, David Group, a junket operator that serves higher-spending casino customers, is closing some rooms in the city, says Bloomberg. Publicly traded companies in the space include Las Vegas Sands (LVS), MGM Resorts (MGM), Wynn Resorts (WYNN) and Melco Crown (MPEL). Reference Link
January 16, 2015
13:32 EDTJOYManning & Napier Advisors reports 6.06% passive stake in Joy Global
Subscribe for More Information
09:11 EDTCELGCelgene says oral Otezla approved by European Commission in 2 indications
Celgene International, a wholly-owned subsidiary of Celgene Corporation, announced that the European Commission has granted marketing authorisation for OTEZLA, the company’s oral selective inhibitor of phosphodiesterase 4, in two therapeutic indications: For the treatment of moderate-to-severe chronic plaque psoriasis in adult patients who failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen and ultraviolet-A light. Alone or in combination with Disease Modifying Antirheumatic Drugs, for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior DMARD therapy. The marketing authorization is based on efficacy and safety data from two Phase III programs, ESTEEM AND PALACE, which demonstrate a maintained clinical response among patients with psoriasis and psoriatic arthritis treated with OTEZLA through 52 weeks, across multiple endpoints. The EC decision follows the positive opinion issued by the Committee for Medicinal Products for Human Use in November 2014.12 OTEZLA will be launched in the European Union in the coming months in accordance with local requirements.
January 15, 2015
17:47 EDTVTRAmerican Realty Capital holders approve merger with Ventas
Subscribe for More Information
14:03 EDTLUVSouthwest fined $1.6M by U.S. DOT for violating tarmac delay rule
Subscribe for More Information
07:59 EDTCELGAmerican Society of Clinical Oncology to hold a symposium
Subscribe for More Information
January 14, 2015
14:02 EDTMGMNew Jersey reports Atlantic City gaming win down 11.2% to $190.5M in December
Subscribe for More Information
09:31 EDTPHParker-Hannifin continues to have risk to 2015 outlook, says Cleveland Research
Subscribe for More Information
07:41 EDTRDCGlobal Hunter Securities to hold a conference
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use